Allos Therapeutics, Inc. Reports Third Quarter 2011 Financial Results

WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (Nasdaq: ALTH) today reported financial results for the three months ended September 30, 2011.

•FOLOTYN® (pralatrexate injection) net product sales increased 61% year-over-year to $13.2 million in the third quarter of 2011, compared to $8.2 million for the same period in 2010. •As of September 30, 2011, the Company had no debt and $100.4 million in total cash, cash equivalents and investments.

Back to news